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Abstract
Background: The immune system is a complex adaptive system of cells and molecules that are interwoven in a highly
organized communication network. Primary immune deficiencies are disorders in which essential parts of the immune
system are absent or do not function according to plan. X-linked agammaglobulinemia is a B-lymphocyte maturation
disorder in which the production of immunoglobulin is prohibited by a genetic defect. Patients have to be put on life-long
immunoglobulin substitution therapy in order to prevent recurrent and persistent opportunistic infections.
Methodology: We formulate an immune response model in terms of stochastic differential equations and perform a
systematic analysis of empirical therapy protocols that differ in the treatment frequency. The model accounts for the
immunoglobulin reduction by natural degradation and by antigenic consumption, as well as for the periodic
immunoglobulin replenishment that gives rise to an inhomogeneous distribution of immunoglobulin specificities in the
shape space. Results are obtained from computer simulations and from analytical calculations within the framework of the
Fokker-Planck formalism, which enables us to derive closed expressions for undetermined model parameters such as the
infection clearance rate.
Conclusions: We find that the critical value of the clearance rate, below which a chronic infection develops, is strongly
dependent on the strength of fluctuations in the administered immunoglobulin dose per treatment and is an increasing
function of the treatment frequency. The comparative analysis of therapy protocols with regard to the treatment frequency
yields quantitative predictions of therapeutic relevance, where the choice of the optimal treatment frequency reveals a
conflict of competing interests: In order to diminish immunomodulatory effects and to make good economic sense,
therapeutic immunoglobulin levels should be kept close to physiological levels, implying high treatment frequencies.
However, clearing infections without additional medication is more reliably achieved by substitution therapies with low
treatment frequencies. Our immune response model predicts that the compromise solution of immunoglobulin substitution
therapy has a treatment frequency in the range from one infusion per week to one infusion per two weeks.
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Introduction
Adaptive immunity implies immune responses against patho-
genic challenges that are antigen-specific and that are memorized
by the immune system. On encounter of antigen, B-lymphocytes
are stimulated to differentiate into plasma cells which produce
large amounts of immunoglobulin. These proteins are specific for
those antigens that stimulate their production and play a key role
in adaptive immunity: Immunoglobulin fights off bacterial
infections by the specific recognition of the invading pathogens,
the neutralization of their harmful effects, and their opsonization
for phagocytosis [1,2].
In order to specifically bind to the vast amount of different
antigens, the molecular structure of immunoglobulin contains a
hypervariable region. This region is generated by random
combinations of gene segments that encode a large variety of
antigen binding sites and that give rise to a highly diverse
repertoire of immunoglobulin. The immunoglobulin binding
affinity for an encountered antigen is dynamically optimized in
the process of affinity maturation that takes place in germinal
centers. Germinal centers are follicular structures in lymphoid
organs where B-lymphocytes undergo the process of somatic
hypermutation with regard to the immunoglobulin hypervariable
region [3–5]. This is followed by the complex process of B-
lymphocyte selection for high-affinity immunoglobulin, which we
only start to unravel today [6]. Successfully selected B-lymphocytes
either differentiate into plasma cells or into long-lived memory
cells. The latter give rise to faster and stronger immune responses
on second encounter of the same antigen. In this way the highly
diverse immunoglobulin repertoire is dynamically adapted to the
host’s current antigenic environment.
In humans, five different immunoglobulin isotypes are distin-
guished that differ in their biological and functional properties [2].
The most prevalent isotype is immunoglobulin G (IgG), which
constitutes about 75% of all serum immunoglobulin and is equally
distributed in blood and in tissue. IgG is the only isotype that
crosses the human placenta thereby protecting the fetus in utero
and providing neonates with passive immunity for the first six
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produce its own immunoglobulin. Thus, rather than being present
at birth, adaptive immunity is an acquired property of the
developing immune system in healthy infants.
Patients with immune deficiencies suffer from recurrent and
persistent infections that develop as the result of a compromised
immune system [7]. For example, X-linked agammaglobulinemia
(XLA) is a primary immune deficiency that is characterized by
absent levels of immunoglobulin for all isotypes [8–10]. This
disease is caused by a mutation of Bruton’s tyrosine kinase (Btk
gene) on the X chromosome [11,12] and affects male and
homozygous female subjects. The genetic defect prohibits the full
maturation of B-lymphocytes such that their vital function in
immunoglobulin adaptation and production remains unaccom-
plished. Recurrent infections in infants starting after the first six
months of life, particularly involving extracellular bacteria, are
typical phenomena belonging to the XLA diagnosis. Untreated
XLA patients are prone to develop severe and life-threatening
infections, however, this risk is significantly lowered by IgG
substitution therapy. The life-long, exogenously induced passive
immunity compensates the absence of adaptive immunity as
mediated by the B-lymphocytes and enables XLA patients to live a
fairly normal life.
Under IgG substitution therapy, a fixed dose of IgG is
periodically administered by infusion, such that the serum IgG
level always remains above a trough level [13–16]. The pool of
immunoglobulin is extracted from the blood products of more than
10
3 human donors in order to reach up to 10
9 different
immunoglobulin specificities [13]. Nowadays, IgG substitution
treatments are performed by intravenous (IV) or subcutaneous
(SC) infusion that both have assets and drawbacks [15,17–19]. For
example, IV infusion allows the administration of large IgG
amounts per treatment such that low treatment frequencies down
to one treatment per four weeks can be achieved. However, this IV
treatment protocol gives rise to high serum IgG peak levels that
significantly exceed the physiological range, but are required in
order to ensure acceptable serum IgG trough levels after four weeks.
The drawback of SC infusion is associated with the limited amount
of IgG that can be administered per treatment and that requires
high treatment frequencies up to two times per week. However, this
also infers serum IgG peak levels that remain close to the
physiological range. Associated with this issue is the observation
that adverse effects are much less reported for SC compared to IV
infusion of IgG[19]. A practical advantage of SC overIV infusionis
that this treatment can be autonomously performed by the patients
and does not require medical supervision.
Besides immune deficiencies a number of autoimmune and
systemic inflammation diseases are as well treated by IgG
substitution therapy, even though it is not yet understood for all
these diseases how IgG exerts its therapeutic impact [13,14]. In
general, the demand for therapeutic use of IgG is increasing at an
annual rate of 5% in Europe and 11% in the US, prophesying that
the current worldwide IgG shortage will pose a serious problem in
the future [20,21]. To optimize IgG consumption the appropriate
dosage window of treatment, which is commonly derived from
empirical trial-and-error methods, should be more precisely
determined by all means. Using a mathematical model approach,
we perform a comparative study of IgG substitution therapies for
XLA patients in order to identify the range of optimal treatment
frequencies. Characteristic features such as the serum IgG peak
level, the dose per treatment, and the impact of fluctuations in the
administered IgG dose are studied. Moreover, we consider the
effect of bacterial infections and calculate the condition for the
development of chronic infections under different IgG substitution
therapies. The range of optimal treatment frequencies is then
identified from the requirement that IgG levels should be kept
close to physiological levels and are still effective at clearing
infections. To our knowledge, we present the first immune
response model for infections under IgG substitution therapy with
a combined analysis of computer simulations and analytical
calculations that permits to make quantitative predictions of
therapeutic relevance.
Methods
Stochastic Immune Response Model
The stochastic immune response model for infections under IgG
substitution therapy accounts for two aspects: (i) the serum IgG
reduction by natural degradation or antigenic consumption, and
(ii) the periodic IgG replenishment that may be subjected to
fluctuations in the administered IgG dose. The model is
schematically depicted in Figure 1A and is translated into a set
of coupled differential equations. Since we are interested in
describing serum IgG levels, this approach, in which spatial
inhomogeneities are neglected, is justified by the fact that
molecules in the blood stream are thoroughly mixed and quickly
circulate on the time scale of 25 seconds [22]. Throughout this
paper we measure concentrations of quantities relative to the
blood volume in units of gram per liter.
The time-dependent serum IgG concentration, Im t ðÞ , obeys the
differential equation
dIm t ðÞ
dt
~{rt ðÞ Im t ðÞ zSm t ðÞ : ð1Þ
The source term Sm t ðÞrepresents the IgG substitution therapy,
where the subscript m refers to the treatment frequency fm of the
therapy protocol. Since the longest time interval between
subsequent IV infusion treatments equals four weeks [14,15], we
set T1~28d and f1~1=T1. In order to compare therapy protocols
with different treatment frequencies, we consider therapy
protocols with multiples of this frequency:
fm~
1
Tm
~mf1~
m
T1
, ð2Þ
where m is a positive integer number. The IgG reduction in Eq. (1)
is represented by the rate rt ðÞ , which consists of two contributions:
rt ðÞ ~rdzrcBm t ðÞ : ð3Þ
Here, rd is the natural IgG degradation rate while the antigenic
consumption depends on the current size of the bacteria
population Bm t ðÞ and the clearance rate rc. Note that the
clearance rate is a reaction rate with unit (concentration6time)
21.
A large variety of sigmoidal growth models exists, describing the
time-dependent growth of specific microbes under various nutrient
conditions [23–25]. In the present context, we do not aim at
modeling specific types of bacteria and apply a logistic growth
model, which is known to capture the generic features of nutrient-
limited bacterial growth beyond the lag-phase [25]. In the
presence of the immune response the time-dependence of the
bacteria population is determined by the differential equation:
dBm t ðÞ
dt
~rpBm t ðÞ 1{
Bm t ðÞ
CB
  
{rcBm t ðÞ Im t ðÞ : ð4Þ
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size with carrying capacity CB in the absence of an immune
response. Note that the subscript m indicates that the time-
evolution of Bm t ðÞis affected through Im t ðÞby the frequency fm of
the therapy protocol.
The IgG substitution therapy is incorporated by the source term
Sm t ðÞ ~
X
n
  I Im n ðÞ
Ti
d
t{nTm
Ti
  
, ð5Þ
where n labels treatments of duration Ti at time points nTm, and
d x ðÞ ~
0f o r x=0
z? for x~0
with
ðz?
{?
d ax {x0 ðÞ ðÞ dx~
1
a jj
 
ð6Þ
is the Dirac distribution. The appearance of the treatment
duration Ti in Eq. (5) is only artificial, since the Dirac distribution
implies that infusion treatments are modeled as instantaneous
processes. This simplification is justified by the fact that Ti is of the
order of hours, whereas the time between subsequent treatments is
of the order of several days, Tm&Ti, and we are ultimately
interested in the time-dependence of Im t ðÞand Bm t ðÞat the time
scale of weeks, t&Tm&Ti.
We account for fluctuations in the administered IgG dose per
treatment,
  I Im n ðÞ ~  I Im 1zc n ðÞ ðÞ , ð7Þ
where Im is the average administered IgG dose per treatment and
c n ðÞ is a Gaussian distributed random variable referring to the nth
treatment. The ensemble average S...Tc yields the mean value
Sc n ðÞ Tc~0 ð8Þ
Figure 1. Schematic representation of the stochastic immune response model under IgG substitution therapy. A: The serum IgG
trough level Lt is maintained by substitution therapy with treatment frequency fm and IgG dose Im per treatment (infusion process: R). The natural
degradation of IgG occurs with rate rd (self-inhibiting process: x) and the binding of IgG to bacteria occurs with clearance rate rc (binding process:
RNr), giving rise to IgG-bacterium complexes that are removed from the system. The bacteria population obeys a logistic growth dynamics that is
characterized by the proliferation rate rp (self-activating process: R) and the carrying capacity CB (self-inhibiting process: x). B: The shape space is an
abstract high-dimensional space, where essential features of IgG binding regions with respect to the considered bacteria species are represented as
points. For reasons of clarity, a two-dimensional shape space is depicted where the two axis represent independent features of IgG binding, such as
charge and size of the binding site. The inhomogeneous IgG shape space distribution under substitution therapy with pooled IgG (bluish area) is
represented by the color intensity (arbitrary units). Even if the total amount of administered IgG per treatment is exactly the same, with respect to a
specific bacterium, i.e. a specific shape space area (red point), fluctuations occur from treatment to treatment.
doi:10.1371/journal.pone.0005685.g001
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Sc n ðÞ c n
0   
Tc~g2dn,n
0, ð9Þ
where
dn,n
0~
0f o rn=n
0
1f o rn~n
0
(
ð10Þ
is the Kronecker delta. The dimensionless constant g denotes the
standard deviation of the Gaussian distribution and is a measure
for the strength of the fluctuations. Thus, Eq. (7) enters the source
term Eq. (5) and represents fluctuations in the total amount of
administered IgG per treatment. As a consequence, Eq. (1) for
Im t ðÞ represents a stochastic differential equation and the
stochasticity of Im t ðÞenters Eq. (4) for Bm t ðÞvia the immune-
response term.
In the population model, we do not explicitly resolve IgG
specificities and different species of bacteria. A detailed description
could be realized within the shape space concept [26]. The shape
space is an abstract high-dimensional space, where essential
features of IgG binding regions with respect to the considered
bacteria species are represented as points. In this spirit, points in
the shape space become occupied by the pooled IgG that is
administered in each treatment. However, the occupation of shape
space points does not necessarily occur in a homogenous fashion.
As is schematically shown in Figure 1B, even for the same total
amount of administered IgG, the amount of IgG that is available
to specific shape space areas can be fluctuating from treatment to
treatment. Since the immune-response term in Eq. (4) is the
product of Bm t ðÞ and Im t ðÞ , the fluctuations Eq. (7) in the
administered IgG dose per treatment can be viewed as an effective
description of shape space inhomogeneities within the population
model.
It is straightforward to compute the time-evolution of the serum
IgG concentration and the bacteria concentration by numerical
integration of Eqs. (1) and (4). Moreover, the advantage of our
model is that it permits to analytically calculate closed expressions
for undetermined quantities such as the clearance rate.
Computer Simulations
We perform simulations of the model Eqs. (1) and (4) using a
self-written algorithm that is based on the fourth-order accurate
Runge-Kutta method [27]. In all simulations the time step of
integration is set to the typical infusion duration per treatment, Ti,
which is estimated to be two hours. The model parameters are
summarized in Table 1 and we checked that our numerical results
are robust against small variations in the parameter values.
Analytical Calculations
Substitution Therapies in the Absence of Infections. In
the absence of infections, the model reduces to Eq. (1) with
Bm t ðÞ ~0 and the source term Eq. (5) for substitution therapy with
frequency Eq. (2). It can be easily verified by differentiation that
the model is solved by the serum IgG concentration
Im t ðÞ ~
  I Im exp {rdt ðÞ
X
n
1zc n ðÞ ðÞ exp rdnTm ðÞ H
t{nTm
Ti
  
,
ð11Þ
where the step function,
H x ðÞ ~
0f o rxv0
1f o rx§0
,
 
ð12Þ
ensures that only treatments n with nTmƒt contribute.
After Nm elapsed treatments, the next treatment takes place at
t~0 and the time-evolution of Im t ðÞduring the interval 0ƒtvTm
is given by
Im t ðÞ ~  I Im exp {rdt ðÞ
X 0
n~{Nm
1zc n ðÞ ðÞ exp rdnTm ðÞ H
t{nTm
Ti
  
~  I Im exp {rdt ðÞ
X Nm
n~0
1zc {n ðÞ ðÞ exp {rdTm ðÞ ðÞ
n:
ð13Þ
The number of treatments scales as Nm~mN1, such that the total
elapsed time, NmTm~N1T1, is equal for all m. In the equilibrated
system the number of elapsed treatments Nm§N1&1= rdT1 ðÞ ,
implying that Eq. (13) reduces to
Im t ðÞ ~  I Im
exp {rdt ðÞ
1{exp {rdTm ðÞ
1z 1{exp {rdTm ðÞ ðÞ
X ?
n~0
c {n ðÞ exp {rdTm ðÞ ðÞ
n
"# ð14Þ
where we used the limiting value of the infinite geometric series.
The ensemble average of Eq. (14) yields
SIm t ðÞ Tc~  I Im
exp {rdt ðÞ
1{exp {rdT1=m ðÞ
, ð15Þ
which is identical to Im t ðÞ in the absence of fluctuations.
Table 1. Overview of model parameters.
parameter description parameter value comment
IgG trough level Lt~8g =l Refs. [13,15,16]
IgG treatment duration Ti~0:083 d simulation time step
IgG treatment frequency fm~m=T1 T1~28 d, m§1
IgG dose per treatment Im adjusted to maintain Lt
IgG dose fluctuation strength g varied
IgG degradation rate rd~0:02 d
{1 Refs. [29,30]
bacteria clearance rate rc varied
bacteria proliferation rate rp~24 d
{1 generic value
bacteria carrying capacity CB~10{2 g=l generic value
time point of infection ti~100 d generic value
initial bacteria population size Bm ti ðÞ ~10{8 g=l generic value
minimal bacteria
population size
Bmin~10{10 g=l estimated
doi:10.1371/journal.pone.0005685.t001
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2 yields
SIm t ðÞ
2Tc~SIm t ðÞ Tc
2 1z 1{exp {rdTm ðÞ ðÞ
2|
"
|
X ?
n
0~0
X ?
n~0
Sc {n
0   
c {n ðÞ T
c
exp {rdTm ðÞ ðÞ
nzn
0
#
~SIm t ðÞ Tc
2 1zg2 1{exp {rdTm ðÞ ðÞ
2
1{exp {2rdTm ðÞ
"#
,
ð16Þ
where we used Eq. (9) and the limiting value of the infinite
geometric series. The expression Eq. (16) gives rise to the relative
variance
sr Im ðÞ ~
SIm t ðÞ
2Tc{SIm t ðÞ Tc
2
SIm t ðÞ Tc
2 ~g2 tanh
rdT1
2m
  
: ð17Þ
Substitution Therapies in the Presence of Infections
In the presence of fluctuations, we solve Eq. (4) with
Im t ðÞ ~SImTTm 1z~ c c t ðÞ ½  , ð18Þ
where we account for fluctuations around the time-averaged
serum IgG concentration SIm t ðÞ TTm according to Eq. (7). Thus,
modulations of Im t ðÞon time scales smaller than Tm are averaged
out while the fluctuations in the administered IgG dose at time
intervals Tm are represented by a continuous function of Gaussian
distributed random numbers with
S~ c c t ðÞ T~ c c~0 and S~ c c t ðÞ ~ c c t
0   
T~ c c~sr Im ðÞ d
t{t
0
Tm
  
ð19Þ
in terms of the relative variance Eq. (17). It is convenient to
perform the variable transformation
bm:
Bm
CB
and t:rpt, ð20Þ
which reduces Eq. (4) to
dbm
dt
~bm 1{
rc
rp
Im
t
rp
     
{b2
m: ð21Þ
This equation can be readily solved by computer simulations for
different random realizations of fluctuations in order to compute
the average size of the bacteria population as a function of time.
Alternatively, we derive and solve the Fokker-Planck equation that
corresponds to Eq. (21) in order to obtain the probability
distribution Pb m, t ðÞ for the time-dependent bacteria population
size.
In general, the probability that the bacteria population has size
bm at time tzDt is given by
Pb m, tzDt ðÞ ~
ð?
0
db
0
mWb m, tzDt b
0
m, t
   
  
Pb
0
m, t
  
, ð22Þ
where Wb m, tzDt b
0
m
    , t
  
denotes the transition probability
from b
0
m to bm during the time interval t to tzDt. For the
Gaussian fluctuations Eq. (19), it can be shown that the transition
probability reduces to the expression [28]:
Wb m, tzDt b
0
m
    , t
  
~d bm{b
0
m
  
{
L
Lbm
S bm tzDt ðÞ {bm t ðÞ ðÞ T~ c cd bm{b
0
m
  
z
1
2
L
2
Lbm
2 S bm tzDt ðÞ {bm t ðÞ ðÞ
2T~ c cd bm{b
0
m
  
:
ð23Þ
Inserting Eq. (23) into Eq. (22) and taking the limit Dt?0 yields
the Fokker-Planck equation:
L
Lt
Pb m, t ðÞ ~
{
L
Lbm
D1 bm ðÞ Pb m, t ðÞ z
L
2
Lbm
2 D2 bm ðÞ Pb m, t ðÞ :
ð24Þ
This equation describes the time-evolution of the probability
distribution Pb m, t ðÞ with initial bacteria concentration
bm ti ðÞ ~Bm ti
 
rp
    
CB at the time point of infection ti~rpti:
Pb m, t ðÞ ~d bm{bm ti ðÞ ðÞ dt {ti ðÞ : ð25Þ
The coefficients in Eq. (24) are defined by
D1 bm ðÞ : lim
Dt?0
Sbm tzDt ðÞ {bm t ðÞ T~ c c
Dt
ð26Þ
and
D2 bm ðÞ :
1
2
lim
Dt?0
S bm tzDt ðÞ {bm t ðÞ ðÞ
2T~ c c
Dt
, ð27Þ
and are derived on the basis of Eq. (21):
bm tzDt ðÞ {bm t ðÞ ~Dt bm 1{
rc
rp
SImTTm
  
{b2
m
  
{
rc
rp
SImTTm
ðtzDt
t
dt
0
bm t
0   
~ c ct
0.
rp
  
:
ð28Þ
We readily obtain
D1 bm ðÞ ~bm 1{
rc
r?
c m ðÞ
  
{b2
m ð29Þ
in terms of the critical clearance rate [cf Eq. (74)],
r?
c m ðÞ :
rp
SImTTm
, ð30Þ
while the only term contributing to Eq. (27),
D2 bm ðÞ ~
SImT
2
Tmr2
c
2r2
p
lim
Dt?0
1
Dt
ðtzDt
t
dt
0
ðtzDt
t
dt
00
bm t
0   
bm t
00   
S~ c ct
0.
rp
  
~ c ct
00.
rp
  
T
~ c c
,
ð31Þ
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D2 bm ðÞ ~cmb2
m: ð32Þ
Here, we defined the dimensionless factor
cm~wm
r2
c
r?
c m ðÞ
2 , ð33Þ
which contains the non-negative quantity wm:sr Im ðÞ rpTm
 
2.
For an equilibrated system, the probability distribution is
obtained from Eq. (24) under the condition
L
Lt
Pb m, t ðÞ ~
L
Lt
Peq bm ðÞ ~0 ð34Þ
or, equivalently, as the solution of
D1 bm ðÞ Peq bm ðÞ ~
L
Lbm
D2 bm ðÞ Peq bm ðÞ : ð35Þ
This equation is trivially solved for bm~0. In particular, in the
absence of fluctuations D2 bm ðÞ ~0 and we readily obtain that
bm~0 is realized for rc~r?
c m ðÞ .
In the presence of fluctuations, Eq. (35) becomes for bm=0:
L
Lbm
Peq bm ðÞ ~
1
cm
^ b bm
bm
{1
"#
Peq bm ðÞ , ð36Þ
with
^ b bm:1{
rc
r?
c m ðÞ
{2cm, ð37Þ
where the distribution has its maximum. The solution of Eq. (36) is
given by
Peq bm ðÞ ~
1
N
exp {
bm{^ b bm ln bm ðÞ
cm
 !
, ð38Þ
where the normalization constant,
N~
ð?
0
dbm exp {
bm{^ b bm ln bm ðÞ
cm
 !
~C
^ b bm
cm
"#
^ b bmc
^ b bm=cm
m , ð39Þ
contains the Gamma function, C x ½  :
Ð ?
0 tx{1e{tdt, which is
valid for xw{1.
We are now in the position to calculate the average size of the
bacteria population,
SBmTPeq~CBSbmTPeq~CB
ð?
0
dbmbmPeq bm ðÞ , ð40Þ
and obtain the result:
SBmTPeq~CB ^ b bmzcm
  
~CB 1{
rc
r?
c m ðÞ
{cm
  
: ð41Þ
Similarly, averaging the square of the bacteria population yields:
SB2
mTPeq~SBmTPeq SBmTPeqzCBcm
  
, ð42Þ
such that the relative variance of the distribution is given by
sr Bm ðÞ ~
SB2
mTPeq{SBmT
2
Peq
SBmT
2
Peq
~
CBcm
SBmTPeq
: ð43Þ
In terms of Eqs. (41)–(43), the probability distribution Eq. (38) can
be written in the form
Peq Bm ðÞ ~
1
N
Bm
CB
   1{sr Bm ðÞ
sr Bm ðÞ
exp {
Bm
SBmTPeqsr Bm ðÞ
 !
, ð44Þ
which can be further reduced to the expression Eq. (75).
Since the condition Eq. (34) entails that the time-dependence of
Pb m, t ðÞ is lost, we estimate the clearance time tc after which the
infection is cleared in the presence of fluctuations. Victorious
fluctuations can compensate for a reduced time-averaged IgG
concentration: S~ I ImTTmƒSImTTm. The condition Eq. (30), which is
valid in the absence of fluctuations, translates in formal analogy to
Eq. (7) into
rp
rc m ðÞ
? ~SImTTm~S~ I ImTTm 1z~ C C
  
: ð45Þ
To estimate the number of treatments required for the victorious
fluctuation to occur, we average the sum of fluctuations for Nc
treatments,
SN c ðÞ :
X Nc{1
n~0
c n ðÞ , ð46Þ
under the constraint that it yields at least the value
~ C C~
SImTTm{S~ I ImTTm
S~ I ImTTm
: ð47Þ
Thus, on average the victorious fluctuation Sv Nc ðÞ is given by
SSv Nc ðÞ Tc~SSN c ðÞ H SN c ðÞ {~ C C
  
Tc ð48Þ
in terms of the step function Eq. (12). The brackets denote the
average
S...Tc~
ðz?
{?
dc 0 ðÞ
ðz?
{?
dc 1 ðÞ ...
ðz?
{?
dc Nc{1 ðÞ ...p c 0 ðÞ ðÞ p c 1 ðÞ ðÞ ...p c Nc{1 ðÞ ðÞ
ð49Þ
with the Gaussian distribution
p c ðÞ ~
1
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2psr Im ðÞ
p exp {
c2
2sr Im ðÞ
  
ð50Þ
in terms of the variance Eq. (17). Using the integral representation
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SSv Nc ðÞ Tc~
lim
e?0z
1
2pi
ðz?
{?
dy
exp i~ C Cy
  
y{ie
S c 0 ðÞ zc 1 ðÞ z...c Nc{1 ðÞ ðÞ |
| exp iyc 0 ðÞ ðÞ exp iyc 1 ðÞ ðÞ ...exp iyc Nc{1 ðÞ ðÞ Tc:
ð51Þ
Taking the average yields
S c 0 ðÞ zc 1 ðÞ z...c Nc{1 ðÞ ðÞ exp iyc 0 ðÞ ðÞ exp iyc 1 ðÞ ðÞ
...exp iyc Nc{1 ðÞ ðÞ Tc~
~iyNcsr Im ðÞ exp {
Nc
2
sr Im ðÞ y2
  
:
ð52Þ
Inserting this expression into Eq. (51) and integrating over y,w e
obtain the result:
SSv tc ðÞ Tc~
~ C C
ﬃﬃﬃﬃﬃﬃ
4p
p C exp {
1
C2
  
, ð53Þ
where we introduced
C:
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2tcmsr Im ðÞ
T1~ C C2
s
ð54Þ
and substituted Nc~tcm=T1.
The condition Eq. (47), according to which the victorious
fluctuation compensates for the reduced time-averaged serum IgG
concentration, implies ~ C C~SSv T ðÞ Tc. In this case, the numerical
solution of Eq. (53) is given by C&3:8, so that Eq. (54) gives rise to
the clearance time
tc&7:2
T1~ C C2
g2m tanh
rdT1
2m
   : ð55Þ
Linearizing the tangens hyperbolicus for rdT1= 2m ðÞ ~0:28=m%1
yields the expression Eq. (87).
Results
Substitution Therapies in the Absence of Infections
We consider IgG substitution therapies that differ in the
treatment frequency in order to compare serum IgG peak levels Lp
and IgG dosages that are required to maintain the serum IgG
trough level Lt. Since it has been reported that XLA patients
require a trough level of Lt~8g =l to prevent recurrent bacterial
infections [13,15,16], we use this value in all calculations.
Similarly, we keep the degradation rate rd~0:02d
{1 fixed in all
calculations. This value is based on the in vivo half-lifetime for IgG
blood products of about 35 days, as consistently reported by the
American Society of Health-System Pharmacists [29] and the
Canadian Blood Services [30].
In the absence of infections and fluctuations in the administered
IgG dose, the model reduces to Eq. (1) with Bm t ðÞ ~0 and the
source term Eq. (5) with g~0 for substitution therapies of
frequency fm. The computed time-evolution of the serum IgG
concentration Im t ðÞis presented in Figure 2A, where we compare
four substitution therapies that differ by the time intervals
T1~28 d, T2~14 d, T4~7d , and T8~3:5d between subse-
quent treatments. For substitution therapy with frequency f1 the
simulation predicts that a dose of I1~6g =l per treatment is
required to maintain the serum IgG trough level Lt. This value is
in agreement with the empirical protocol of IV infusion therapy,
which prescribes 0.4 g IgG per kg body weight every four weeks
[14,15]. For an adult person with a body weight of 75 kg and a
blood volume of 5 liters, this implies 30 g IgG per treatment and
equals the administered serum IgG concentration of 6 g/l. For
substitution therapies with higher frequencies, the simulations
predict IgG doses per treatment of I2~2:58 g=l for f2,
I4~1:2g =l for f4, and I8~0:58 g=l for f8. In the case of
substitution therapy with treatment frequency f4 this corresponds
to 0.08 g IgG per kg body weight every week and compares
reasonably well with extended studies reporting weekly doses in
the range 0.051 to 0.147 g IgG per kg body weight [15]. Note that
even for comparable body masses, due to the variability in IgG
pharmacokinetics, the required IgG dosage always depends on the
individual patient. Nevertheless, our simulations have a firm
quantitative basis and reproduce values that are in agreement with
the range of values obtained from extended experimental studies.
This remains true if a constant background of bacteria is taken into
account and will be discussed below.
The numerical results of our simulations are confirmed by the
analytical solution of the model as derived in the Methods Section
[cf Eq. (14)]. It can be rigorously calculated that the serum IgG
concentration between two subsequent treatments, 0ƒtvTm,i s
given by:
Im t ðÞ ~Im
exp {rdt ðÞ
1{exp {rdT1=m ðÞ
: ð56Þ
In order to compare different substitution therapies, we measure
the trough level of the serum IgG concentration at t~Tm:
Lt:Im Tm ðÞ , ð57Þ
imposing the condition that each treatment maintains the same
trough level Lt. For the IgG dose per treatment Im, this implies the
central relation
Im~Lt 1z
I1
Lt
   1=m
{1
"#
ð58Þ
in terms of the IgG dose I1. This formula reproduces the
aforementioned values obtained from the simulations and,
moreover, can be used to express characteristic quantities in the
comparison of substitution therapies fm and fm
0. For example, the
relative difference in the IgG doses per treatment is given by
dt m, m
0   
:
Im{Im
0
Im
0
, ð59Þ
and the relative difference in the time-integrated IgG doses is given
by
di m, m
0   
:
fmIm{fm
0Im
0
fm
0Im
0
: ð60Þ
We plot dt m,1 ðÞ and di m,1 ðÞ in Figure 2B and observe that the
amount of substituted IgG is reduced in therapies with higher
IgG Substitution Therapy
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example, under substitution therapy with frequency f8 the time-
integrated dose is reduced by 23% as compared to f1. Per
treatment the IgG dose is even reduced by more than 90% for
substitution therapy with frequency f8 as compared to f1. A lower
IgG dose per treatment has direct consequences for the IgG peak
level
Lp m ðÞ :LtzIm~Lt 1z
I1
Lt
   1=m
: ð61Þ
This exponentially decreasing function of m is plotted in Figure 2C.
The comparison of substitution therapy f1 versus f8 reveals a
significant difference in the increase relative to the physiological
trough level Lt of 75% versus 7%, respectively. In absolute
numbers this corresponds to Lp 1 ðÞ ~14 g=l and Lp 8 ðÞ ~8:56 g=l
and is in agreement with the range of values found in experiment
[13,15]. During the time interval 0ƒtvTm the serum IgG
concentration drops from Lp m ðÞ to Lt, where the corresponding
time-averaged serum IgG concentration is defined by
SIm t ðÞ TTm:
1
Tm
ðTm
0
dtIm t ðÞ ~
mIm
ln 1z I1
Lt
   : ð62Þ
As can be seen in Figure 2C, the relative deviation of SIm t ðÞ TTm
from the trough level Lt is only 3.6% for substitution therapy f8,
which is an order of magnitude smaller than for substitution
therapy f1 with 34%.
Next, we consider the case where fluctuations in the
administered IgG dose per treatment are present. As can be
observed in Figure 2D for all substitution therapies with the same
fluctuation strength g~0:2, the serum IgG trough level Lt is still
maintained on average. However, variations of Im t ðÞaround Lt
are larger for substitution therapies with lower frequency fm. This
observation can be quantified by the analytical solution of the
model as presented in the Methods Section [cf Eq. (17)]. We find
that the serum IgG concentration between two subsequent
Figure 2. Comparison of serum IgG concentrations for different substitution therapies in the absence of infections. A: Simulation
results based on Eq. (1) with Bm t ðÞ ~0 and the source term Eq. (5) for different substitution therapies in the absence of fluctuations (g~0). The
frequencies of the substitution therapies are: f1 (black line), f2 (red line), f4 (green line), and f8 (blue line). B: Analytical calculation of the relative
difference in the IgG doses per treatment dt m,1 ðÞ (red line) and time-integrated di m,1 ðÞ (green line) for different substitution therapies according to
Eqs. (59) and (60), respectively. C: Analytical calculation of the serum IgG peak level Lp m ðÞ (red line) and the time-averaged dose SIm t ðÞ TTm (green
line) for different substitution therapies according to Eqs. (61) and (62), respectively. D: The same as in A but in the presence of fluctuations in the
administered IgG amount per treatment with fluctuation strength g~0:2.
doi:10.1371/journal.pone.0005685.g002
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with the relative variance
sr Im ðÞ ~
SIm t ðÞ
2Tc{SIm t ðÞ Tc
2
SIm t ðÞ Tc
2
~g2 tanh
rdT1
2m
  
^0:28
g2
m
:
ð63Þ
Here, we used that rdT1= 2m ðÞ ~0:28=m%1 to approximate the
tangens hyperbolicus in the last step. Thus, for a fixed fluctuation
strength g of the administered IgG dose Im, the impact on the
variation of Im t ðÞdecreases as 1=m for substitution therapies with
larger frequencies fm. This is a consequence of the fact that in
substitution therapies with lower frequency, a single fluctuation
determines the time-evolution of Im t ðÞover a longer period of
time. The implications of fluctuations in the presence of infections
are further analyzed below.
Substitution Therapies in the Presence of Infections
We investigate the conditions for which infections under IgG
substitution therapy are either cleared or develop into chronic
infections with a finite concentration of bacteria surviving the
immune response. In all simulations the bacteria population is
initially absent until the time point of infection at ti~100 d. Then,
starting from this time point, a finite bacteria population is
proliferating and triggering the immune response. We choose the
parameter values Bm ti ðÞ ~10{8 g=l and CB~10{2 g=l, implying
for a typical cell weight of 10
29 g a starting value of about 10
2
bacterial cells that can grow to a population of roughly 10
8
bacterial cells. With this in mind, in the simulations we set
Bm t ðÞ ~0 whenever Bm t ðÞattains values below Bmin:10{10 g=l.
The bacteria proliferation rate is chosen to be rp~24 d
{1 and the
clearance rate rc is varied.
Neglect of fluctuations in the administered IgG dose. In
the absence of fluctuations (g~0), we compare the immune
response under different substitution therapies. Typical simulation
results are plotted in Figure 3 for substitution therapy with
frequency f1 (black line) and f8 (blue line). Choosing a high value
for the clearance rate, rc~4:0d g =l ðÞ
{1, the proliferation of
bacteria is strongly suppressed under both substitution therapies
resulting into the fast extinction of the bacteria population and a
virtually unaffected dynamics of the serum IgG concentration
(Figures 3A and 3B).
The situation is different for low clearance rates, where a
chronic infection develops that is accompanied by a decrease in
the serum IgG concentration. This is shown in Figures 3C and 3D
for the clearance rate rc~1:0d g =l ðÞ
{1 and is qualitatively similar
under both substitution therapies. Due to the immune response
the growth of the bacteria population is limited to a size lower than
the carrying capacity CB. Note that the concentration Bm t ðÞis
modulated by the repeated IgG infusions and has an average value
that is slightly larger for substitution therapy f8 as compared to f1.
The serum IgG trough level for substitution therapy f1 is slightly
more reduced than for substitution therapy f8. This is a general
feature which can be explained in the limit of a constant bacteria
population Bm t ðÞ ~B with dBm t ðÞ =dt~0. The trough level in the
presence of a constant bacteria population follows directly from
Eqs. (56) and (57):
Im Tm ðÞ
Lt
~
exp rdTm ðÞ {1
exp rdzrcBm ðÞ Tm ðÞ {1
: ð64Þ
For small concentrations B%1= rcTm ðÞ , we obtain to lowest order
in the size of the bacteria population:
Im Tm ðÞ
Lt
&1{Fr dTm ðÞ
rcB
rd
, ð65Þ
where we defined
Fx ðÞ :
x exp x ðÞ
exp x ðÞ {1
: ð66Þ
This is a strictly monotonically increasing function of x. Thus, as
can be expected, a small constant background of bacteria results
only into a modest decrease of the serum IgG trough level.
However, as follows from the functional dependence of
Fr dT1=m ðÞ on m, the decrease of the trough level is less
pronounced for substitution therapies with higher frequency fm.
This result is preserved in the limit of a strong chronic infection,
B&1= rcTm ðÞ , where Eq. (64) can be approximated by
Im T1 ðÞ
Lt
& exp
rdT1
m
  
{1
  
exp {
rcBT1
m
  
: ð67Þ
In this limit, the immune response against infections consumes
significantly more IgG than is lost by its natural degradation.
Therefore, the serum IgG trough level becomes exponentially
suppressed indicating that the immune response fails to clear the
infection.
Interestingly, qualitative differences for the two substitution
therapies f1 and f8 are observed at intermediate values of the
clearance rate rc. In Figures 3E and 3F we plot the result for
rc~2:5d g =l ðÞ
{1 and find that a chronic infection develops for
substitution therapy f8 accompanied by a decrease in the
corresponding serum IgG trough level. In contrast, for substitution
therapy f1 the initially increasing bacteria population is eventually
cleared by the immune response. Shortly after the IgG infusion
treatment at day 112 the infection is cleared, even though until this
time the bacteria population had grown to a size that is
comparable to the final population size of the chronic infection
under substitution therapy f8.
We investigate the transition from a cleared infection to a
chronic infection as a function of the clearance rate rc. This is
done by computing the time-averaged value
SBm t ðÞ TT~
1
Dt
ðTzDt
T
dtBm t ðÞ ð 68Þ
in the time interval TƒtƒTzDt. The parameters of the time
interval are chosen such that the system has time to equilibrate, i.e.
we start at time point T~400 days and consider a time interval of
Dt~100 days. For different substitution therapies the results are
shown in Figure 4 as a function of rc. We find that the critical
clearance rate above which chronic infections do not develop
depends on the frequency fm of the applied substitution therapy.
Higher frequencies fm require higher values of rc for the clearance
of the infection.
The immune response model for infections under IgG
substitution therapy can be solved analytically. After a sufficiently
long time the system has equilibrated in response to the infection.
Modulations of Im t ðÞon time scales smaller than Tm are averaged
out by replacing Im t ðÞin Eq. (4) with the time-averaged serum IgG
concentration SIm t ðÞ TTm. This renders the solution of the
differential equation (4) a trivial task. The relevant parameter,
IgG Substitution Therapy
PLoS ONE | www.plosone.org 9 May 2009 | Volume 4 | Issue 5 | e5685Figure 3. Simulation results of the immune response to infection for different clearance rates rc in the absence of fluctuations in the
administered IgG dose per treatment. The serum IgG concentration Im t ðÞand the bacteria population Bm t ðÞare plotted as a function of time
and for substitution therapies with frequencies f1 (black line) and f8 (blue line). A and B: Limit of high clearance rate with rc~4:0d g =l ðÞ
{1. Within one
day the infection is cleared by extinction of the growing bacteria population under both substitution therapies. C and D: Limit of low clearance rate
with rc~1:0d g =l ðÞ
{1. A chronic infection rapidly develops under both substitution therapies which is accompanied by a reduced serum IgG trough
level. E and F: In the intermediate regime of clearance rates with rc~2:5d g =l ðÞ
{1 a qualitative difference is observed between substitution therapies
with frequencies f1 and f8. The former succeeds in clearing the infection within 14 days time, whereas the latter can not hold the bacteria population
at bay such that a chronic infection develops.
doi:10.1371/journal.pone.0005685.g003
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immune response, is given by the ratio of the bacteria proliferation
rate to the clearance rate,
K:
rp
rc
, ð69Þ
and does not depend on the carrying capacity CB.
In the limit of a sufficiently strong immune response with
SIm t ðÞ TTm§K, bacteria are cleared faster than they can
proliferate resulting into the complete extinction of the population.
In this case the decay of the bacteria population is given by
Bm t ðÞ ~
smCBBm 0 ðÞ exp {smrpt
  
smCBzBm 0 ðÞ1{exp {smrpt
      , ð70Þ
where we introduced the non-negative parameter
sm:
SIm t ðÞ TTm
K
{1
       
       : ð71Þ
This parameter depends on the applied substitution therapy and
determines how fast the bacteria population becomes extinct. For
finite values of sm, the time at which the infection is cleared,
Bm t ðÞ ?0, scales as tc!1
 
smrp
  
.
In the limit of a weak immune response, 0vSIm t ðÞ TTmvK, the
bacteria population attains a finite size indicating the development
of a chronic infection. The solution of Eq. (4) is given by
Bm t ðÞ ~
smCBBm 0 ðÞ exp smrpt
  
smCBzBm 0 ðÞexp smrpt
  
{1
   , ð72Þ
such that Bm t ðÞ ?smCB after sufficiently long times t&1
 
smrp.
Thus, a weak immune response has two effects on the bacteria
population: (i) It gives rise to a retardation of the population
growth by the scaling factor sm, and (ii) it ultimately results into a
chronic infection, where the size of the bacteria population,
smCBvCB, is smaller than in the absence of immune responses.
The transition from a system with a cleared infection to a system
with a chronic infection is determined from sm~0,o r
SIm t ðÞ TTm~K: ð73Þ
In Figure 5A we plot K as a function of rc for three different values
of the proliferation rate rp. The crossing points of K with
SIm t ðÞ TTm for the four substitution therapies with frequencies f1,
f2, f4, and f8 are indicated for different values of the proliferation
rate rp. There is quantitative agreement between the values
obtained from the simulations (Figure 4) and the calculated values
for rp~24 d
{1. The crossing points define the critical clearance
rate r?
c m ðÞ and using Eqs. (62), (69), and (73) we obtain the
analytical expression:
r?
c m ðÞ ~rp ln 1z
I1
Lt
  
1
mIm
: ð74Þ
The dependence of the critical clearance rate on the bacteria
proliferation rate rp is observed in Figure 5A, implying that the
success of clearing an infection under substitution therapy with
frequency fm strongly depends on the virulency of the bacteria.
Note, however, that the critical clearance rate does not depend on
the carrying capacity CB.
In Figure 5B we plot the ratio r?
c m ðÞ
 
r?
c 1 ðÞto illustrate the
difference between substitution therapies with frequencies fm.I n
particular, we find that the clearance of infection under
substitution therapy with frequency f8 requires the critical
clearance rate to be about 30% larger as compared to substitution
therapy with frequency f1 under otherwise identical conditions.
This quantitative analysis explains the qualitatively different results
of the simulations for the serum IgG concentration and the
bacteria population presented in Figure 3. For rp~24 d
{1,w e
obtain from Eq. (74) that r?
c 1 ðÞ ~2:24 dg=l ðÞ
{1 and
r?
c 8 ðÞ ~2:90 dg=l ðÞ
{1. The numerical calculations in Figure 3A–
3B and Figure 3C–3D are performed for parameters
rc~4:0d g =l ðÞ
{1wr?
c 1 ðÞ , r?
c 8 ðÞ and rc~1:0d g =l ðÞ
{1vr?
c 1 ðÞ ,
r?
c 8 ðÞ , respectively, and give rise to qualitatively comparable
results under both substitution therapies. In contrast, the
numerical calculation in Figure 3E–3F is performed for the
clearance rate rc~2:50 dg=l ðÞ
{1 with rcwr?
c 1 ðÞbut rcvr?
c 8 ðÞ ,
which explains the success of substitution therapy f1 and the failure
of substitution therapy f8 to clear the bacterial infection.
Impact of fluctuations in the administered IgG dose. In
the presence of fluctuations, we compare the immune response
under substitution therapies with frequencies f1 and f8. Typical
simulation results are plotted in Figure 6. These are obtained for
the fluctuation strength g~0:2 and for clearance rates rc that
would induce a chronic infection in the absence of fluctuations. As
can be deduced from Figure 4, a finite bacteria population size of
about 30% of the carrying capacity CB implies that
Figure 4. Simulation results for the time-averaged size of the
bacteria population in the equilibrated system. The time-
averaged size of the bacteria population, SBm t ðÞ TT, is computed as a
function of the clearance rate rc according to Eq. (68). The proliferation
rate rp~24 d
{1 and the carrying capacity CB~10{2 g=l are kept fixed
in the computations for different substitution therapies with frequen-
cies f1 (black line), f2 (red line), f4 (green line), and f8 (blue line). It is
clearly observed that the critical value of the clearance rate with
SBm t ðÞ TT~0 depends on the treatment frequency.
doi:10.1371/journal.pone.0005685.g004
IgG Substitution Therapy
PLoS ONE | www.plosone.org 11 May 2009 | Volume 4 | Issue 5 | e5685rc~2:0d g =l ðÞ
{1 for substitution therapy with frequency f1 and
rc~2:83 dg=l ðÞ
{1 for f8.
In Figures 6A and 6B, we plot Im t ðÞ and Bm t ðÞ for
rc~2:0d g =l ðÞ
{1 and for substitution therapies with frequencies
f1 (black line) and f8 (blue line). While in the absence of
fluctuations a chronic infection would develop under both
substitution therapies, in the presence of fluctuations this is only
observed for substitution therapy with frequency f8. The
substitution therapy with frequency f1 gives rise to the extinction
of the bacteria population, where the infection is cleared 43 days
after the time point of infection at ti~100 d. During this time
period the bacteria population size is fluctuating over many orders
of magnitude and even reaches values close to 30% of CB but is
ultimately cleared. Note that under substitution therapy with
frequency f8 the bacteria population grows to 56% of CB, which
corresponds to the size expected in the absence of fluctuations
(Figure 4).
Increasing the clearance rate to rc~2:83 dg=l ðÞ
{1, we plot in
Figures 6C and 6D the corresponding simulation results for Im t ðÞ
and Bm t ðÞ . For both substitution therapies the extinction of the
bacteria population is observed, where the infection is cleared
within 1 day for substitution therapy with frequency f1 and within
3 days for f8. However, we stress that different random realizations
in the administered IgG dose per treatment can give rise to very
different courses of the infection. For example, in Figures 6E and
6F we show the results for parameter values that are identical to
the ones used in Figures 6C and 6D but for a different random
realization in the administered IgG dose per treatment. In this case
it takes about 44 days before the infection is cleared by substitution
therapy with frequency f8. In general, different random realiza-
tions give rise to large variations in the infection duration that can
exceed months and years. Therefore, even though the infection
may be ultimately cleared, it may still have to be treated as a
chronic infection in the sense that additional medication is
necessary to clear the infection on a reasonable time scale. This
issue will be further addressed below.
The simulations suggest that the critical clearance rate in the
presence of fluctuations, ~ r r?
c m ðÞ , is reduced compared to the case of
absent fluctuations: ~ r r?
c m ðÞ vr?
c m ðÞ . Conversely, it can be argued
that for the same clearance rate infections are cleared by time-
averaged serum IgG concentrations in the presence of fluctuations,
S~ I ImTTm, that are lower compared to SImTTm in the absence of
fluctuations. The reason for this being that in the course of time
fluctuations can be both to the disadvantage and to the advantage
of infection clearance. However, once an infection has been
cleared, the bacteria population has died out and is defeated for
ever. As is observed in Figure 6, infections are in fact cleared by
victorious fluctuation that happen to occur in the course of time.
For example, analyzing substitution therapy with frequency f1 in
Figure 6A, the current peak level at the time point of infection is
relatively low and is only increasing above average values in the
subsequent treatment at day 140, which then leads to the
immediate clearance of the infection. For substitution therapy
with frequency f8 in Figure 6C, such a victorious fluctuation
happens to occur around the time point of infection resulting into
the immediate clearance of the infection, whereas in Figure 6E it
takes until day 125 before a victorious fluctuation is established
that ultimately defeats the infection.
Analytical results are obtained by translating the stochastic
differential equation (4) into the corresponding Fokker-Planck
equation [28]. The latter describes the time-evolution of the
probability distribution PB m, t ðÞ for the time-dependent survival
of a bacteria population under the immune response. The
derivation of the stationary probability distribution Peq Bm ðÞ for
the equilibrated system is presented in the Methods Section [cf Eq.
(44)]. Here, we readily give the final expression in a compact form:
Peq z ðÞ ~
1
N
z
1{sr
sr exp {
z
sr
  
, ð75Þ
where the normalization constant N~s
1=sr
r C s{1
r
  
contains the
Gamma-function C x ½  :
Ð ?
0 tx{1e{tdt. Furthermore, we use the
scaled variable
z:
Bm
SBmTPeq
, ð76Þ
while the parameter of the distribution corresponds to the relative
variance
Figure 5. Analytical results for the critical clearance rates in the absence of fluctuations. A: The intersections between SIm t ðÞ TTm
(horizontal lines) and K~rp
 
rc (grey lines) indicate the critical clearance rates (crossing points) according to Eq. (73). This is shown for different values
of rp and substitution therapies with frequencies f1 (black line), f2 (red line), f4 (green line), and f8 (blue line). B: Comparison of substitution therapies
with different treatment frequencies fm by the ratio r?
c m ðÞ
 
r?
c 1 ðÞaccording to Eq. (74).
doi:10.1371/journal.pone.0005685.g005
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SB2
mTPeq{SBmT
2
Peq
SBmT
2
Peq
: ð77Þ
Interestingly, two distinct regimes of Peq z ðÞare identified that are
visualized in Figure 7. For srw1 the probability distribution Eq.
(75) diverges at z~0, such that the extinction of the bacteria
population is most likely to occur in this regime. In contrast, for
Figure 6. Simulation results of immune responses to infections for different clearance rates rc in the presence of fluctuations in the
administered IgG dose per treatment with fluctuation strength g~0:2. The serum IgG concentration Im t ðÞand the bacteria population Bm t ðÞ
are plotted as function of time and for substitution therapies with frequencies f1 (black line) and f8 (blue line). A and B: For clearance rate
rc~2:0d g =l ðÞ
{1 the infection is cleared after 43 days under substitution therapy with frequency f1, whereas a chronic infection develops under
substitution therapy with frequency f8. C and D: For clearance rate rc~2:83 dg=l ðÞ
{1 the infection is cleared within 1 and 3 days under substitution
therapy with frequency f1 and f8, respectively. E and F: For the same parameters as in C and D but for a different random realization of fluctuations in
the administered IgG dose per treatment. Even though the infection is ultimately cleared, this is only achieved after 44 days under substitution
therapy with frequency f8.
doi:10.1371/journal.pone.0005685.g006
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the extinction of the bacteria population is impossible and a
chronic infection is established. The abrupt transition between
these two regimes is induced by the fluctuations and occurs at
sr~1, where Peq z ðÞequals the exponential distribution with a
finite value at z~0.
The average size of the bacteria population has been calculated
in the Methods Section [cf Eq. (41)] and yields in terms of the
model parameters:
SBmTPeq~CB 1{
rc
r?
c m ðÞ
{wm
r2
c
r?
c m ðÞ
2
 !
, ð78Þ
where the non-negative quantity
wm~sr Im ðÞ
rpT1
2m
ð79Þ
contains the relative variance Eq. (63). Note that, due to the fluc-
tuations, the bacteria population vanishes already at lower values of
the clearance rate as compared to r?
c m ðÞ in the absence of fluctuations
(wm~0). The critical clearance rate in the presence of fluctuations is
calculated from the condition SBmTPeq~0 and is given by:
~ r r?
c m ðÞ ~G wm ½  r?
c m ðÞ : ð80Þ
Here, we defined the strictly monotonic function
Gx ½  :
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1z4x
p
{1
2x
with Gx ½  ƒ1f o rx§0, ð81Þ
such that ~ r r?
c m ðÞ vr?
c m ðÞ in the presence of fluctuations. Note that,
since G wm ½  increases with larger values of m, the effect of fluctuations
is more pronounced for substitution therapies with lower frequencies
fm. This can be seen in Figure 8A, where we plot the ratio
~ r r?
c m ðÞ
 
r?
c 1 ðÞas a function of m and for different values of the
fluctuation strength g. For a given fluctuation strength, infections are
cleared for clearance rates above the solid line. There is quantitative
agreement between the clearance rates used in the simulations with
fluctuation strength g~0:2 ( F i g u r e6 )a n dt h ev a l u e so b t a i n e df r o m
the analytical calculations (Figure 8A). For example, for substitution
therapy with frequency f1 we used rc
 
r?
c 1 ðÞ ~0:89 in the simulations.
This value is below ~ r r?
c 1 ðÞ
 
r?
c 1 ðÞ ~1 for g~0 but above
Figure 7. Qualitative change in the equilibrium probability
distribution Peq z ðÞ . The equilibrium probability distribution Eq. (75) is
plotted for different values of the parameter sr. For sr~0:05 (red line)
the distribution vanishes, Peq z?0 ðÞ ?0, indicating that the infection is
not cleared. For sr~2:0 (green line) the distribution diverges,
Peq z?0 ðÞ ??, making the clearance of infection the most likely event.
The transition occurs for sr~1 (black line) where Peq z ðÞequals the
exponential distribution.
doi:10.1371/journal.pone.0005685.g007
Figure 8. Analytical results for the critical clearance rates in the presence of fluctuations. A: The ratio~ r r?
c m ðÞ
 
r?
c 1 ðÞ [cf Eq. (80)] reveals that
the critical clearance rate decreases with increasing fluctuation strength g~0 (black line), g~0:1 (red line), g~0:2 (green line), and g~0:3 (blue line).
B: For clearance rates above ~ r r?
c m ðÞ
 
~ r r?
c 1 ðÞ(solid lines) the infection is cleared [cf Eq. (80)], whereas a chronic infection develops for clearance rates
below r?
c m ðÞ
 
~ r r?
c 1 ðÞ (dashed lines) [cf Eq. (84)]. The dependence of the critical clearance rate on the applied substitution therapy becomes increasingly
significant for increasing fluctuation strength g~0 (black line), g~0:1 (red line), g~0:2 (green line), and g~0:3 (blue line).
doi:10.1371/journal.pone.0005685.g008
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c 1 ðÞ
 
r?
c 1 ðÞ ~0:40 for g~0:2. Correspondingly, for substitution
therapy with frequency f8 we used rc
 
r?
c 1 ðÞ ~1:26,w h i c hi sb e l o w
~ r r?
c 1 ðÞ
 
r?
c 1 ðÞ ~1:30 for g~0 but above ~ r r?
c 1 ðÞ
 
r?
c 1 ðÞ ~1:23 for
g~0:2.
In order to compare substitution therapies in the presence of
fluctuations among each other, we plot the ratio ~ r r?
c m ðÞ
 
~ r r?
c 1 ðÞin
Figure 8B as solid lines. It is important to notice that, in comparison
to the case of absent fluctuations, the difference between substitution
therapies in the presence of fluctuations is significantly larger. For
g~0 we found that the clearance of infection under substitution
therapy with frequency f8 implies that the critical clearance rate is
about 30% larger as compared to substitution therapy with frequency
f1 (Figure 5B). However, for fluctuation strength g~0:1, g~0:2,a n d
g~0:3 the critical clearance rate under substitution therapy with
frequency f8 is increased by, respectively, 100%, 200%, and 300%
relative to the substitution therapy with frequency f1.
Next, as is shown in the Methods Section [cf Eq. (42)], the
calculation of the average square of the bacteria population
concentration yields
SB2
mTPeq~SBmTPeq SBmTPeqzCBwm
r2
c
r?
c m ðÞ
2
 !
, ð82Þ
such that the relative variance becomes
sr Bm ðÞ ~
SB2
mTPeq{SBmT
2
Peq
SBmT
2
Peq
~
CBwm
SBmTPeq
r2
c
r?
c m ðÞ
2 : ð83Þ
The variance diverges for SBmTPeq?0 indicating the transition
from a chronic infection to the extinction of the bacteria
population. The extinction of the bacteria population is impossible
for sr Bm ðÞ v1 and the clearance rate that separates the two
regimes follows from the condition sr Bm ðÞ ~1, or:
  r rc m ðÞ :G 2wm ½  r?
c m ðÞ , ð84Þ
with Gx ½ as defined in Eq. (81). In Figure 8B, the ratio
  r rc m ðÞ
 
~ r r?
c 1 ðÞis plotted as dashed lines for the different fluctuation
strengths g. The model predicts that for clearance rates below the
dashed lines a chronic infection develops. For clearance rates
above the solid lines the bacteria population becomes extinct by
the immune response. In the narrow regime between the dashed
and solid lines the bacteria population may either become extinct
or attain a finite size.
Thederivationofthe equilibriumprobabilitydistributionEq.(75)
entails that all time-dependent information is lost. As has been
stated above, an infection might be cleared at some day but the
duration of infection may exceed months and years. We estimate
the clearance time in the presence of fluctuations that compensate
for a reduced time-averaged IgG concentration: S~ I ImTTmƒSImTTm.
The condition Eq. (73), which was derived in the absence of
fluctuations, translates in formal analogy to Eq. (7) into
K~SImTTm~S~ I ImTTm 1z~ C C
  
: ð85Þ
From the viewpoint of the bacteria population, the non-negative
factor
~ C C~
SImTTm{S~ I ImTTm
S~ I ImTTm
ð86Þ
can be interpreted as a measure for inhomogeneities in the IgG shape
space distribution. In order to clear the infection, the deficit ~ C C has to
be compensated by victorious fluctuations in the course of time. The
time for such a victorious fluctuation to emerge during Nc infusion
treatments defines the clearance time: tc:NcTm.I ti ss h o w ni nt h e
Methods Section that tc can be calculated by averaging the sum of
fluctuations for Nc subsequent treatments under the constraint that
this sum compensates for the deficit ~ C C. We obtain the resulting
expression [cf Eq. (55)]:
tc&14:4
~ C C2
rdg2 , ð87Þ
which is independent of the treatment frequency. In Figure 9 we plot
tc for different values of the fluctuation strength g in the range ~ C C~0
(or: S~ I ImTTm~SImTTm)t o~ C C~0:5 (or: S~ I ImTTm^0:67SImTTm). A
clearance time in the order of days is only obtained for ~ C C-values of a
few percent. For ~ C C~0:1,o rS~ I ImTTm^0:9SImTTm,t h ee s t i m a t e d
clearance time already amounts to about 80 days, 6 months, and 2
years for fluctuation strengths g~0:3, g~0:2,a n dg~0:1,
respectively. Thus, in the presence of fluctuations infections are
cleared that would otherwise become chronic, however, since the
time required for a victorious fluctuation to emerge can exceed
months, fluctuations do not represent a failsafe mechanism of
infection clearance.
Discussion
Applying a stochastic immune response model, we perform a
comparative study of IgG substitution therapies. The combined
analysis of computer simulations and analytical calculations
permits to make quantitative predictions that are of therapeutic
relevance. We base our model on data that are obtained from
Figure 9. Infection clearance time as a function of shape space
inhomogeneities for different values of the fluctuation
strength. The clearance time tc [cf Eq. (87)] as a function of ~ C C [cf Eq.
(86)] for different fluctuation strengths g~0:1 (red line), g~0:2 (green
line), and g~0:3 (blue line). For ~ C C larger than a few percent, the
duration of infection rapidly exceeds months and years.
doi:10.1371/journal.pone.0005685.g009
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our knowledge, clinical studies where serum IgG levels of a
sufficiently large group of patients are monitored for reasonably
long times under IgG substitution therapy with varying treatment
frequencies do not yet exist. This may be related to the fact that
XLA, with an estimated number of 1500 new patients per year
worldwide, is a relatively rare immune deficiency. Therefore,
mathematical modeling represents the ideal tool for simulating and
optimizing IgG substitution therapies under uniquely defined
conditions. As a general result of this approach, the behavior of
selected quantities is predicted and motivates purposeful experi-
ments.
For IgG substitution therapies with different treatment frequen-
cies we compare serum peak levels and IgG dosages that are
required to maintain the same serum trough level. In general, we
find that the amount of substituted IgG is reduced for substitution
therapies with higher treatment frequencies, both per treatment
and also time-integrated (Figure 2B). Thus, against the back-
ground of the current worldwide IgG shortage and the
continuously increasing high costs in the order of 100 US $ per
gram IgG [20,21], substitution therapies with high treatment
frequencies are preferable. In particular, for substitution therapy
with two treatments per week relative to substitution therapy with
one treatment per four weeks, we find that the IgG dose per
treatment is reduced by more than 90% and the time-integrated
dose is reduced by more than 20%. This has direct consequences
for the serum IgG peak level and the time-averaged serum IgG
concentration. Both quantities are exponentially decreasing with
the frequency of the substitution therapy (Figure 2C). Comparing
again substitution therapies with two treatments per week and with
one treatment per four weeks, we obtain a significant difference in
the increase of the serum IgG peak level relative to the
physiological trough level of 7% versus 75%, respectively.
Similarly, we find an order of magnitude difference in the
deviation of the time-averaged serum IgG concentration from the
trough level, which is only 3.6% for substitution therapy with two
treatments per week as compared to 34% for substitution therapy
with one treatment per four weeks. In general, it can be deduced
from Figure 2B and 2C that the characteristic quantities quickly
level off for treatment frequencies above once per two weeks.
All these findings support IgG substitution therapies with high
treatment frequencies for which the IgG consumption is reduced
and where therapeutic serum IgG levels are kept close to
physiological levels. This is highly desirable since the precise
mechanisms behind immunomodulatory effects of administered
IgG are not yet understood, however, it is generally accepted that
administered IgG does interfere with the immune system at many
different levels [14,31,32]. For example, administered IgG has
inhibitory effects on antigen presentation [33], on T cell activation
[32,34,35], on cellular cross-talk via the cytokine network [36,37],
and on phagocytosis via the IgG fragment crystallizable (Fc) region
[32,38,39]. In general, impaired immune regulation by Fc
receptors leads to unresponsiveness or hyperreactivity to non-self
as well as self antigens [40]. Moreover, it is reported that
administered IgG promotes apoptosis in lymphocytes and
monocytes [32,41]. Taken together, there is sufficient reason for
keeping serum IgG levels close to the physiological level.
It should be kept in mind, however, that the primary goal of IgG
substitution therapy in XLA patients is the prevention of
opportunistic infections. At this point we exploit the advantage
of mathematical modeling where different substitution therapies in
the presence of bacterial infections can be analyzed under identical
conditions as a function of the clearance rate. In general, the value
of the clearance rate, which depends on microscopic details of the
binding between IgG and antigenic epitopes [42], is not known.
We vary this parameter and find that the infection is cleared under
any IgG substitution therapy for sufficiently high clearance rates.
However, a critical value of the clearance rate exists below which a
chronic infection develops that is accompanied with a decrease in
the IgG trough level. As can be seen in Figure 3C and Figure 3D,
the bacteria population survives the immune response and grows
by a factor 10
6, while the IgG trough level is only lowered by a
factor 0.75. We conclude that small changes in the trough level
can be associated with large changes in the bacteria population.
Therefore, monitoring the serum IgG trough level in XLA patients
on a regular basis provides information for the early detection of
infections by systematic deviations.
Our analytical calculations reveal that the critical clearance rate
strongly depends on the virulency of the bacteria, since it is
proportional to the bacteria proliferation rate. Most importantly,
however, the critical clearance rate depends on the applied
substitution therapy, as we consistently show by numerical
(Figure 4) and analytical (Figure 5) calculations. In general, a
higher critical clearance rate is required for substitution therapies
with higher treatment frequencies. This supports IgG substitution
therapies with low treatment frequencies in order to optimize the
prevention of chronic infections. For example, the substitution
therapy with two treatments per week requires the critical
clearance rate to be about 30% larger as compared to substitution
therapy with one treatment per four weeks (Figure 5B). The
difference between substitution therapies becomes even more
significant in the presence of fluctuations in the administered IgG
dose. Comparing the same substitution therapies as before, the
predicted increase in the critical clearance rate is of the order of
several hundreds of percent with the exact value depending on the
fluctuation strength (Figure 8). Therefore, ignoring the potential
impact of immunomodulatory effects and the important issue of
IgG shortage, treatment frequencies well below once per week are
preferred.
The differences in the critical clearance rate for different
substitution therapies are minimized by keeping the fluctuations in
the administered IgG dose per treatment small. From the
viewpoint of the considered bacteria species, these fluctuations
can also be interpreted to effectively model dynamic inhomoge-
neities of the IgG shape space distribution during the immune
response (Figure 1B). Even if the time-averaged serum IgG
concentration in the relevant shape space area is smaller than is
required for the clearance of the infection, it may nevertheless be
cleared in the course of time due to victorious fluctuations. Thus,
in principle, due to the presence of fluctuations infections are
cleared that would otherwise become chronic. However, our
model predicts that only small inhomogeneities of the order of
several percent are balanced by victorious fluctuations on a
reasonable time scale. For larger inhomogeneities the time
required for clearing the infection can easily exceed months
(Figure 9), making additional medication necessary to clear the
infection on a reasonable time scale. A side effect of fluctuations is
that systematic deviations in the monitored serum IgG trough level
get blurred (Figure 6).
In conclusion, the stochastic immune response model empha-
sizes the importance of elaborate IgG pooling in order to achieve a
highly homogeneous IgG shape space distribution for the reliable
clearance of infections on a reasonable time scale. For XLA
patients the choice of the treatment frequency is a trade-off
between competing interests: On the one hand, therapeutic IgG
levels should be kept close to physiological levels in order to
diminish immunomodulatory effects and to make good economic
sense. This is realized by substitution therapies with high treatment
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are effective at clearing infections is to be maximized. This is
achieved by substitution therapies with low treatment frequencies.
Taken together, our model suggests that the compromise solution
with regard to the treatment frequency of IgG substitution therapy
for XLA patients ranges from once per week to once per two
weeks.
We finally note that the stochastic immune response model is a
first step that can be improved in various ways. For example, the
time-evolution of the serum IgG concentration could be more
realistically represented in the shape space of IgG specificities to
model the simultaneous infection by different bacteria species
explicitly. Furthermore, the impact of immunomodulatory effects
due to high serum IgG peak levels could be included into the
model and analyzed by a comparative study of substitution
therapies. Leaving these and related issues for future research, the
present study already represents a conclusive example for the
potential of mathematical modeling in optimizing empirical IgG
treatment protocols. On the basis of our analysis, we suggest
clinical studies where the same group of XLA patients is
monitored during sufficiently long times for infections and serum
IgG levels under different IgG substitution therapies within the
specified range of optimal treatment frequencies.
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